Aminosalicylate drugs, particularly mesalazine, may be used for the induction and maintenance of remission in Crohn's disease.
European evidence-based consensus group and a Cochrane systematic review haven’t found any evidence that aminosalicylates (such as mesalazine) are superior to placebo at maintaining remission in people with medically-induced remission of Crohn’s disease (1).
Mesalazine has been found to reduce relapses after surgery (especially after small bowel resection) (2).
NICE state (3):
maintaining remission in Crohn's disease after surgery
Last reviewed 01/2018